FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980204064> ?p ?o ?g. }

• W2980204064 endingPage "579" @default.
• W2980204064 startingPage "579" @default.
• W2980204064 abstract "Abstract Two major clinical limitations to the use of thrombolytic agents are their short half-life and lack of targeting specificity. We aimed to circumvent these limitations by targeting a platelet-bound, thrombin-activatable, low molecular weight urokinase, termed PLT/uPA-T, to nascent thrombi by a combination of two strategies: (1) Attaching the drug through its N-terminal scFv portion to human αIIb/β3 on the surface of platelets with nM affinity. (2) Protecting the uPA from rapid activation/inactivation in the circulation while simultaneously requiring its activation by thrombin through a two amino acid deletion at the plasmin cleavage site that concurrently creates a thrombin cleavage/activation site. These two properties constrain the activity of PLT/uPA-T on mature clots, which express low levels of thrombin and transiently recruit only a few new platelets to the shell rather than the core of the thrombus. These two properties of PLT/uPA-T also enhance the drug’s lifespan by attaching it to the platelet cell surface and preventing its inactivation before reaching its intended target. PLT/uPA-T binds specifically to human platelets and to hαIIb mouse platelets that transgenically expressed human (h) αIIb on its surface. In hαIIb mice, the half-life of retro-orbitally infused PLT/uPA-T was ~2 hours, ~100-fold longer than similarly infused uPA-T and did not cause any spontaneous bleeding or lower platelet counts 4 to 24 hours later. We now report two in vivo models to test the efficacy of the PLT/uPA-T as a thromboprophylactic agent versus uPA-T, taking into account the much shorter circulating half-life of the latter. In the hαIIb mice model, a tail-vein clipping model was done to represent the “mature clot” as follows: following clipping, blood was collected into 37°C water for 10 minutes. The tail was then removed from the water and a bolus of PLT/uPA-T (0.5 µg/g mouse) injected retro-orbitally followed by a continuous infusion of the same dose over the next 30 minutes. uPA-T was similarly infused but both bolus and infusion were given at 10-fold higher doses. A no-drug treatment control was also included. After the drug infusion was started, the tail was placed into fresh 37°C water and bleeding was documented from these “mature clots” over the ensuing 30 minutes. To study “nascent thrombi”, mice were bolused/infused with same drug regimens, and a FeCl3 carotid artery injury study was performed contemporaneously. PLT/uPA-T was as effective at 1/10th the dose as uPA-T at preventing these “nascent thrombi” (FeCl3 injuries), but did not cause bleeding from “mature clots” (tail clippings) relative to the no-treatment control, while the uPA-T treatment lead to ~5-fold greater rebleeding compared to the no-treatment control (p<0.001) with N > 10 animals per arm. The second in vivo model targeted human platelets infused into immunocompromized NOD-SCID γ-interferon-deficient (NSG) male mice to generate a calculated 10% of all the circulating platelets being human at the initiation of the studies. The pre-drug “mature clots” and the post-drug “nascent thrombi” were both arteriolar laser cremaster injuries. We enumerated mouse platelets incorporated into these thrombi over time. There was an ~50% decrease in the size of laser-induced post-drug “nascent thrombi” after PLT/uPA-T or a 10-fold higher dose of uPA-T relative to no drug treatment. However, PLT/uPA-T did not affect the size of the laser-induced pre-drug “mature clots” relative to no drug-treatment, while there was a decrease in size of the mature clots after treatment with uPA-T. These studies describe two preclinical models of comparative thromboprophylactic efficacy and safety that are independent of drug half-life. Our studies demonstrate that a combination of platelet-targeting and need for thrombin-activation makes PLT/uPA-T a very potent and targeted thrombolytic agent to prevent new thrombus formation, while leaving older, hemostatic clots intact. Disclosures No relevant conflicts of interest to declare." @default.
• W2980204064 created "2019-10-18" @default.
• W2980204064 creator A5014680035 @default.
• W2980204064 creator A5022924802 @default.
• W2980204064 creator A5030315782 @default.
• W2980204064 creator A5052209957 @default.
• W2980204064 creator A5062598528 @default.
• W2980204064 creator A5077478635 @default.
• W2980204064 creator A5090155288 @default.
• W2980204064 date "2014-12-06" @default.
• W2980204064 modified "2023-09-27" @default.
• W2980204064 title "A Human-Specific, Platelet-Targeted, Thrombin-Activatable Urokinase (PLT/uPA-T) Demonstrates Selective Thromboprophylactic Properties in Two in Vivo Models" @default.
• W2980204064 doi "https://doi.org/10.1182/blood.v124.21.579.579" @default.
• W2980204064 hasPublicationYear "2014" @default.
• W2980204064 type Work @default.
• W2980204064 sameAs 2980204064 @default.
• W2980204064 citedByCount "0" @default.
• W2980204064 crossrefType "journal-article" @default.
• W2980204064 hasAuthorship W2980204064A5014680035 @default.
• W2980204064 hasAuthorship W2980204064A5022924802 @default.
• W2980204064 hasAuthorship W2980204064A5030315782 @default.
• W2980204064 hasAuthorship W2980204064A5052209957 @default.
• W2980204064 hasAuthorship W2980204064A5062598528 @default.
• W2980204064 hasAuthorship W2980204064A5077478635 @default.
• W2980204064 hasAuthorship W2980204064A5090155288 @default.
• W2980204064 hasBestOaLocation W29802040641 @default.
• W2980204064 hasConcept C126322002 @default.
• W2980204064 hasConcept C1491633281 @default.
• W2980204064 hasConcept C150903083 @default.
• W2980204064 hasConcept C153911025 @default.
• W2980204064 hasConcept C181199279 @default.
• W2980204064 hasConcept C185592680 @default.
• W2980204064 hasConcept C203014093 @default.
• W2980204064 hasConcept C207001950 @default.
• W2980204064 hasConcept C2776892390 @default.
• W2980204064 hasConcept C2777292125 @default.
• W2980204064 hasConcept C2781071845 @default.
• W2980204064 hasConcept C3018697912 @default.
• W2980204064 hasConcept C55493867 @default.
• W2980204064 hasConcept C56219504 @default.
• W2980204064 hasConcept C71924100 @default.
• W2980204064 hasConcept C86803240 @default.
• W2980204064 hasConcept C89560881 @default.
• W2980204064 hasConcept C98274493 @default.
• W2980204064 hasConceptScore W2980204064C126322002 @default.
• W2980204064 hasConceptScore W2980204064C1491633281 @default.
• W2980204064 hasConceptScore W2980204064C150903083 @default.
• W2980204064 hasConceptScore W2980204064C153911025 @default.
• W2980204064 hasConceptScore W2980204064C181199279 @default.
• W2980204064 hasConceptScore W2980204064C185592680 @default.
• W2980204064 hasConceptScore W2980204064C203014093 @default.
• W2980204064 hasConceptScore W2980204064C207001950 @default.
• W2980204064 hasConceptScore W2980204064C2776892390 @default.
• W2980204064 hasConceptScore W2980204064C2777292125 @default.
• W2980204064 hasConceptScore W2980204064C2781071845 @default.
• W2980204064 hasConceptScore W2980204064C3018697912 @default.
• W2980204064 hasConceptScore W2980204064C55493867 @default.
• W2980204064 hasConceptScore W2980204064C56219504 @default.
• W2980204064 hasConceptScore W2980204064C71924100 @default.
• W2980204064 hasConceptScore W2980204064C86803240 @default.
• W2980204064 hasConceptScore W2980204064C89560881 @default.
• W2980204064 hasConceptScore W2980204064C98274493 @default.
• W2980204064 hasIssue "21" @default.
• W2980204064 hasLocation W29802040641 @default.
• W2980204064 hasOpenAccess W2980204064 @default.
• W2980204064 hasPrimaryLocation W29802040641 @default.
• W2980204064 hasRelatedWork W2018891963 @default.
• W2980204064 hasRelatedWork W2085864855 @default.
• W2980204064 hasRelatedWork W2124292364 @default.
• W2980204064 hasRelatedWork W2149382568 @default.
• W2980204064 hasRelatedWork W2318157174 @default.
• W2980204064 hasRelatedWork W2371302129 @default.
• W2980204064 hasRelatedWork W2419966270 @default.
• W2980204064 hasRelatedWork W2433780668 @default.
• W2980204064 hasRelatedWork W2980204064 @default.
• W2980204064 hasRelatedWork W4253149402 @default.
• W2980204064 hasVolume "124" @default.
• W2980204064 isParatext "false" @default.
• W2980204064 isRetracted "false" @default.
• W2980204064 magId "2980204064" @default.
• W2980204064 workType "article" @default.